Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 09 Nov 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: 10%+ Owner
Signature: Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol: ACRV
Transactions as of: 09 Nov 2022
Net transactions value: $0
Form type: 3
Filing time: 09 Nov 2022, 19:51:08 UTC
Previous filing: 03 Aug 2021
Next filing: 21 Nov 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ACRV	Series B Preferred Stock							09 Nov 2022	Common Stock	888,130		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 1-for-2.466 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.